$220.16
-3.72-1.66%
At close: -
$220.16
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
West Pharmaceutical Servs Analyst Ratings and Price Targets | NYSE:WST | Benzinga
West Pharmaceutical Services Inc has a consensus price target of $365.13 based on the ratings of 9 analysts. The high is $536 issued by Jefferies on February 7, 2024. The low is $250 issued by Deutsche Bank on December 14, 2022. The 3 most-recent analyst ratings were released by Evercore ISI Group, Keybanc, and Citigroup on March 18, 2025, February 14, 2025, and January 8, 2025, respectively. With an average price target of $333.33 between Evercore ISI Group, Keybanc, and Citigroup, there's an implied 51.41% upside for West Pharmaceutical Services Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Evercore ISI Group
Keybanc
Citigroup
B of A Securities
UBS
1calculated from analyst ratings
Analyst Ratings for West Pharmaceutical Servs
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/18/2025 | Buy Now | 24.91% | Evercore ISI Group | Daniel Markowitz15% | → $275 | Initiates | → Outperform | Get Alert |
| 02/14/2025 | Buy Now | 47.62% | Keybanc | Paul Knight55% | $470 → $325 | Maintains | Overweight | Get Alert |
| 01/08/2025 | Buy Now | 81.69% | Citigroup | Thomas Palmer43% | → $400 | Initiates | → Buy | Get Alert |
| 12/13/2024 | Buy Now | 61.25% | B of A Securities | Derik De Bruin84% | $350 → $355 | Maintains | Buy | Get Alert |
| 12/13/2024 | Buy Now | — | Wolfe Research | Doug Schenkel71% | — | Initiates | → Peer Perform | Get Alert |
| 12/12/2024 | Buy Now | 77.14% | UBS | John Sourbeer32% | $350 → $390 | Upgrade | Neutral → Buy | Get Alert |
| 02/16/2024 | Buy Now | 70.33% | UBS | John Sourbeer32% | $400 → $375 | Maintains | Neutral | Get Alert |
| 02/13/2024 | Buy Now | 113.48% | Keybanc | Paul Knight55% | $440 → $470 | Maintains | Overweight | Get Alert |
| 02/07/2024 | Buy Now | 143.46% | Jefferies | David Windley74% | $323 → $536 | Upgrade | Hold → Buy | Get Alert |
| 10/27/2023 | Buy Now | 77.14% | Stephens & Co. | Jacob Johnson57% | $420 → $390 | Maintains | Overweight | Get Alert |
| 08/30/2023 | Buy Now | 99.85% | Keybanc | Paul Knight55% | $415 → $440 | Maintains | Overweight | Get Alert |
| 08/21/2023 | Buy Now | 88.5% | Keybanc | Paul Knight55% | $385 → $415 | Maintains | Overweight | Get Alert |
| 07/28/2023 | Buy Now | 74.87% | Keybanc | Paul Knight55% | $375 → $385 | Maintains | Overweight | Get Alert |
| 07/17/2023 | Buy Now | 90.77% | Stephens & Co. | Jacob Johnson57% | $400 → $420 | Maintains | Overweight | Get Alert |
| 06/16/2023 | Buy Now | 83.96% | B of A Securities | Derik De Bruin84% | $390 → $405 | Upgrade | Neutral → Buy | Get Alert |
| 04/11/2023 | Buy Now | 81.69% | Stephens & Co. | Jacob Johnson57% | $330 → $400 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 02/17/2023 | Buy Now | 70.33% | Keybanc | Paul Knight55% | $315 → $375 | Maintains | Overweight | Get Alert |
| 12/14/2022 | Buy Now | 13.55% | Deutsche Bank | Justin Bowers49% | → $250 | Initiates | → Hold | Get Alert |
| 12/02/2022 | Buy Now | 43.08% | Keybanc | Paul Knight55% | $350 → $315 | Maintains | Overweight | Get Alert |
| 11/30/2022 | Buy Now | 13.55% | UBS | John Sourbeer32% | → $250 | Initiates | → Neutral | Get Alert |
| 10/28/2022 | Buy Now | 13.55% | B of A Securities | Derik De Bruin84% | $385 → $250 | Downgrade | Buy → Neutral | Get Alert |
| 10/28/2022 | Buy Now | 58.98% | Keybanc | Paul Knight55% | $400 → $350 | Maintains | Overweight | Get Alert |
| 07/29/2022 | Buy Now | 56.7% | Stephens & Co. | Jacob Johnson57% | $330 → $345 | Maintains | Equal-Weight | Get Alert |
| 04/29/2022 | Buy Now | 86.23% | B of A Securities | Derik De Bruin84% | $475 → $410 | Maintains | Buy | Get Alert |
| 04/29/2022 | Buy Now | 81.69% | Keybanc | Paul Knight55% | $475 → $400 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for West Pharmaceutical Servs (WST) stock?
The latest price target for West Pharmaceutical Servs (NYSE:WST) was reported by Evercore ISI Group on March 18, 2025. The analyst firm set a price target for $275.00 expecting WST to rise to within 12 months (a possible 24.91% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for West Pharmaceutical Servs (WST)?
The latest analyst rating for West Pharmaceutical Servs (NYSE:WST) was provided by Evercore ISI Group, and West Pharmaceutical Servs initiated their outperform rating.
When was the last upgrade for West Pharmaceutical Servs (WST)?
The last upgrade for West Pharmaceutical Services Inc happened on December 12, 2024 when UBS raised their price target to $390. UBS previously had a neutral for West Pharmaceutical Services Inc.
When was the last downgrade for West Pharmaceutical Servs (WST)?
The last downgrade for West Pharmaceutical Services Inc happened on October 28, 2022 when B of A Securities changed their price target from $385 to $250 for West Pharmaceutical Services Inc.
When is the next analyst rating going to be posted or updated for West Pharmaceutical Servs (WST)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of West Pharmaceutical Servs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for West Pharmaceutical Servs was filed on March 18, 2025 so you should expect the next rating to be made available sometime around March 18, 2026.
Is the Analyst Rating West Pharmaceutical Servs (WST) correct?
While ratings are subjective and will change, the latest West Pharmaceutical Servs (WST) rating was a initiated with a price target of $0.00 to $275.00. The current price West Pharmaceutical Servs (WST) is trading at is $220.16, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.